Core Insights - Elicio Therapeutics is progressing towards an interim analysis focused on disease-free survival in the Phase 2 AMPLIFY-7P clinical trial, expected in Q3 2025, which is a significant milestone for the company and patients with pancreatic ductal adenocarcinoma [1][2] - The company has aligned with the FDA on key design elements for a planned Phase 3 study of ELI-002, indicating regulatory support for its development [1][8] - Elicio's current cash position of $18.4 million is expected to support operations into Q4 2025, beyond the anticipated interim analysis [6][7] Financial Performance - Research and development expenses for Q1 2025 were $7.8 million, a slight increase from $7.6 million in Q1 2024, primarily due to clinical trial costs [4] - General and administrative expenses rose to $3.0 million in Q1 2025 from $2.7 million in Q1 2024, attributed to higher compensation and benefits [5] - The net loss for Q1 2025 was $11.2 million, compared to $11.8 million in Q1 2024, with a net loss per share of $0.87, down from $1.15 in the previous year [6][10] Clinical Development - ELI-002 is being studied as a potential treatment for mKRAS-driven tumors, with the upcoming interim data readout in PDAC seen as a critical validation opportunity for the AMP platform [2][8] - The company plans to finalize the pivotal Phase 3 trial protocol for ELI-002 in resected mKRAS PDAC in the second half of 2025 [8][19] - Elicio's AMP technology aims to enhance the immune response against cancer by delivering antigens directly to lymph nodes, which may lead to improved therapeutic outcomes [16][17] Corporate Updates - In March 2025, Elicio appointed Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, indicating a strengthening of its leadership team [8] - The company raised $10 million through a registered direct offering of common stock and warrants in January 2025, bolstering its cash position [8]

Core Viewpoint - Elicio Therapeutics (ELTX) has experienced a recent decline in share price, but the formation of a hammer chart pattern suggests a potential trend reversal due to increased buying interest and positive earnings estimate revisions from analysts [1][2]. Technical Analysis - The hammer chart pattern indicates a possible bottoming out of the stock, with reduced selling pressure and a shift in control from bears to bulls [2][5]. - This pattern is characterized by a small candle body with a long lower wick, suggesting that the stock found support after hitting a new low during a downtrend [4][5]. - Hammer candles can appear on various timeframes and are relevant for both short-term and long-term investors [5]. Fundamental Analysis - There has been a notable upward trend in earnings estimate revisions for ELTX, which is a bullish indicator suggesting potential price appreciation [7]. - Over the last 30 days, the consensus EPS estimate for the current year has increased by 9.9%, indicating that analysts expect better earnings than previously predicted [8]. - ELTX holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [9].

Core Insights - Elicio Therapeutics has granted inducement awards to its newly appointed Chief Strategy and Financial Officer, Preetam Shah, and two additional employees as part of their employment agreement [1][2] - The inducement awards consist of 191,624 stock options for Dr. Shah and a total of 21,000 stock options for the other two employees, with an exercise price of $4.98 per share [2] - The stock options will vest over four years, with 25% vesting on the first anniversary of the respective start dates and the remainder vesting monthly thereafter [3] Company Overview - Elicio Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for high-prevalence cancers, including mKRAS-positive pancreatic and colorectal cancers [4] - The company aims to leverage its Amphiphile ("AMP") technology to enhance the activation of cancer-specific T cells, promoting durable cancer immunosurveillance [4] - Elicio's lead program, ELI-002, targets common KRAS mutations found in approximately 25% of all solid tumors and is currently in a randomized clinical trial for patients with mKRAS-positive pancreatic cancer [4]

Company Performance - Elicio Therapeutics (ELTX) has returned approximately 7.8% year-to-date, outperforming the average gain of 0.9% in the Medical sector [4] - The Zacks Consensus Estimate for ELTX's full-year earnings has increased by 23% over the past quarter, indicating improved analyst sentiment and a stronger earnings outlook [3] Industry Context - Elicio Therapeutics is part of the Medical - Biomedical and Genetics industry, which consists of 509 individual stocks and currently ranks 75 in the Zacks Industry Rank [6] - Stocks in the Medical - Biomedical and Genetics industry have experienced an average loss of about 0.3% year-to-date, highlighting ELTX's superior performance within this group [6] Comparative Analysis - Inventiva S.A. Sponsored ADR (IVA) is another Medical stock that has significantly outperformed the sector, with a year-to-date return of 41.1% [4] - The consensus EPS estimate for Inventiva S.A. has increased by 40.1% over the past three months, and it also holds a Zacks Rank of 2 (Buy) [5]

Core Viewpoint - Elicio Therapeutics (ELTX) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements, making it a valuable tool for investors [2][4]. - The recent upgrade for Elicio Therapeutics reflects an improvement in the company's earnings outlook, likely leading to an increase in its stock price [5][10]. Earnings Estimate Revisions - For the fiscal year ending December 2025, Elicio Therapeutics is projected to earn -$2.79 per share, representing a 34.4% change from the previous year's reported figure [8]. - Over the past three months, the Zacks Consensus Estimate for Elicio Therapeutics has increased by 23%, indicating a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - Elicio Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].

Core Insights - Elicio Therapeutics has made significant advancements in its cancer immunotherapy pipeline, notably completing enrollment in its first randomized Phase 2 clinical trial, AMPLIFY-7P, which is expected to yield interim analysis results in Q3 2025 [2][5] - The company has aligned with the FDA on key elements for the Phase 3 study design of ELI-002, focusing on dose, patient population, and primary endpoint analysis [1][5] - Elicio has strengthened its cash position, with expectations to support operations into Q4 2025, beyond the upcoming interim analysis [1][8] Recent Highlights - Elicio presented promising Phase 1a data for ELI-002, showing a strong correlation between T cell response and anti-tumor activity across two monotherapy trials involving 39 patients [2] - The Phase 2 AMPLIFY-7P trial has successfully enrolled 144 patients with post-resection mKRAS pancreatic ductal adenocarcinoma, randomized 2:1 to receive ELI-002 or standard care [5] - Updated results from the Phase 1a AMPLIFY-201 trial indicated a median recurrence-free survival of 16.3 months and a median overall survival of 28.9 months [5] Financial Overview - Research and development expenses for 2024 were $33.7 million, up from $23.8 million in 2023, primarily due to clinical trial costs [6] - General and administrative expenses decreased slightly to $11.3 million in 2024 from $11.9 million in 2023 [6] - The net loss for 2024 was $51.9 million, compared to $35.2 million in 2023, with a net loss per share of $4.25 [7] Cash Position - As of December 31, 2024, Elicio had cash and cash equivalents of $17.6 million, an increase from $12.9 million in 2023 [7][10] - The company anticipates that its current cash position, bolstered by a $10 million direct offering in January 2025, will support operations into Q4 2025 [8] Upcoming Milestones - The DFS event-driven interim analysis for the Phase 2 AMPLIFY-7P trial is expected in Q3 2025, contingent on the rate of event accrual [5] - Elicio aims to finalize the pivotal Phase 3 trial protocol for ELI-002 in resected mKRAS pancreatic ductal adenocarcinoma in the second half of 2025 [5]

BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, effective as of the date hereof. Dr. Shah brings a wealth of leadership experience to Elicio after previously serving as chief financial officer, chief business officer, and i ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has entered into definitive securities purchase agreements with institutional investors for the purchase of an aggregate of 1,261,830 shares of its common stock and accompanying warrants to purchase up to an aggregate of 1,261,830 shares of its common st ...

Core Insights - Elicio Therapeutics has received supportive FDA feedback on the design of the Phase 3 study for ELI-002, which includes key elements such as dose, schedule, patient population, and primary endpoint analysis [1][2] - The Phase 2 randomized study of ELI-002 is fully enrolled, with an interim analysis of disease-free survival expected in the first half of 2025; positive results could lead to rapid advancement into Phase 3 development [1][2] Company Overview - Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment, particularly targeting high-prevalence cancers like mKRAS-positive pancreatic and colorectal cancers [3] - The company aims to leverage recent clinical successes in personalized cancer vaccines to create effective off-the-shelf vaccines [3] - Elicio's lead program, ELI-002, targets common KRAS mutations, which are responsible for approximately 25% of all solid tumors [3][4] Product Details - ELI-002 is an investigational AMP cancer vaccine designed to target cancers driven by KRAS mutations, utilizing Elicio's proprietary AMP technology [4] - The ELI-002 7P formulation is currently being studied in a Phase 1/2 trial for patients with mKRAS-driven pancreatic cancer, aiming to provide immune response coverage against seven common KRAS mutations [5] Technology Platform - Elicio's AMP platform is designed to deliver immunotherapeutics directly to lymph nodes, enhancing the education and activation of immune cells [6][8] - The platform has shown potential in preclinical models to drive therapeutic immune responses with increased magnitude, function, and durability [6][8] - Originally developed at the Massachusetts Institute of Technology, the AMP platform has broad potential for advancing various cancer treatment initiatives [7]